Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting.
Cancer family history
Genetic testing
Medical history taking
Medical records
Pedigree
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
01
12
2021
revised:
07
02
2022
accepted:
09
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
The literature demonstrates that the quality of cancer family history (CFH) as currently collected in the outpatient setting is inadequate to assess disease risk. Prior to implementation of a web-based application for cancer family history collection, we aimed to review the quality of collected CFH in a gynecologic oncology outpatient clinic and determine contributing patient factors. Medical records were reviewed for 200 new patients presenting between 4/2019-7/2019. CFH was collected during the patient interview and evaluated for inclusion of eight elements based on standards set by the genetics community. Univariate and multivariable linear regression analyses were utilized to evaluate the effect of patient characteristics on the number of relatives included in the CFH. Among our cohort of 200 patients, CFH was documented for 185 patients (92.5%). On univariate analysis, patients with a family history of cancer and prior genetic testing had significantly greater median number of relatives included in the CFH. On multivariable analysis, patients with family members with cancer had significantly more relatives included. Our data are consistent with the literature, suggesting that the current collection methods may not adequately capture all measures of a high quality CFH. Patients reporting no family history of cancer and those without prior genetic testing were least likely to have CFH that included key quality elements and these patients might benefit from health information technology CFH collection tools.
Identifiants
pubmed: 35242980
doi: 10.1016/j.gore.2022.100941
pii: S2352-5789(22)00021-2
pmc: PMC8861387
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100941Subventions
Organisme : NCI NIH HHS
ID : K07 CA216326
Pays : United States
Informations de copyright
© 2022 The Authors. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Prim Care. 2004 Sep;31(3):479-95, vii-viii
pubmed: 15331243
Am J Prev Med. 2004 Oct;27(3):239-45
pubmed: 15450637
Fam Pract. 1997 Aug;14(4):285-8
pubmed: 9283847
Obstet Gynecol. 2019 Dec;134(6):1366-1367
pubmed: 31764755
Mol Genet Genomic Med. 2020 Aug;8(8):e1315
pubmed: 32468681
Int J Gynecol Cancer. 2012 Feb;22(2):254-9
pubmed: 22274317
Acad Med. 2000 Aug;75(8):850-2
pubmed: 10965867
Genet Med. 2011 Sep;13(9):785-93
pubmed: 21555944
J Clin Oncol. 2014 Mar 10;32(8):824-9
pubmed: 24493722
Obstet Gynecol. 2014 Nov;124(5):1042-1054
pubmed: 25437740
Obstet Gynecol. 2017 Sep;130(3):e110-e126
pubmed: 28832484
Community Genet. 2007;10(3):174-80
pubmed: 17575462
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Obstet Gynecol. 2015 Jan;125(1):282-283
pubmed: 25560146
JAMA Oncol. 2018 Jun 1;4(6):876-879
pubmed: 29710084